CLC number:
On-line Access: 2024-08-27
Received: 2023-10-17
Revision Accepted: 2024-05-08
Crosschecked: 2022-01-25
Cited: 0
Clicked: 966
Chi B. Ahn, Ji-Hyun Lee, Joo H. Kim, Tae H. Kim, Hee-Sook Jun, Kuk H. Son & Jin W. Lee . Development of a 3D subcutaneous construct containing insulin-producing beta cells using bioprinting[J]. Journal of Zhejiang University Science D, 2022, 5(2): 265-276.
@article{title="Development of a 3D subcutaneous construct containing insulin-producing beta cells using bioprinting",
author="Chi B. Ahn, Ji-Hyun Lee, Joo H. Kim, Tae H. Kim, Hee-Sook Jun, Kuk H. Son & Jin W. Lee ",
journal="Journal of Zhejiang University Science D",
volume="5",
number="2",
pages="265-276",
year="2022",
publisher="Zhejiang University Press & Springer",
doi="10.1007/s42242-021-00178-9"
}
%0 Journal Article
%T Development of a 3D subcutaneous construct containing insulin-producing beta cells using bioprinting
%A Chi B. Ahn
%A Ji-Hyun Lee
%A Joo H. Kim
%A Tae H. Kim
%A Hee-Sook Jun
%A Kuk H. Son & Jin W. Lee
%J Journal of Zhejiang University SCIENCE D
%V 5
%N 2
%P 265-276
%@ 1869-1951
%D 2022
%I Zhejiang University Press & Springer
%DOI 10.1007/s42242-021-00178-9
TY - JOUR
T1 - Development of a 3D subcutaneous construct containing insulin-producing beta cells using bioprinting
A1 - Chi B. Ahn
A1 - Ji-Hyun Lee
A1 - Joo H. Kim
A1 - Tae H. Kim
A1 - Hee-Sook Jun
A1 - Kuk H. Son & Jin W. Lee
J0 - Journal of Zhejiang University Science D
VL - 5
IS - 2
SP - 265
EP - 276
%@ 1869-1951
Y1 - 2022
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1007/s42242-021-00178-9
Abstract: type 1 diabetes is caused by insulin deficiency due to the loss of beta cells in the islets of Langerhans. In severe cases, islet transplantation into the portal vein is performed. However, due to the loss of transplanted islets and the failure of islet function, the 5-year insulin independence rate of these patients is?50%. In this study, we developed a long-term, insulin-secreting, 3D-bioprinted construct implanted subcutaneously with the aim of preventing islet loss. The bioprinted construct was fabricated by the multi-layer bioprinting of beta-cell (mouse insulinoma-6: MIN-6)-encapsulated alginate bioink and poly(caprolactone) biodegradable polymer. A glucose response assay revealed that the bioprinted constructs proliferated and released insulin normally during the 4-week in vitro period. Bioprinted MIN-6 generated clusters with a diameter of 100200 m, similar to the original pancreatic islets in the construct. In an in vivo study using type 1 diabetes mice, animals implanted with bioprinted constructs showed three times higher insulin secretion and controlled glucose levels at 8 weeks after implantation. Because the implanted, bioprinted constructs had a positive effect on insulin secretion in the experimental animals, the survival rate of the implanted group (75%) was three times higher than that of the non-implanted group (25%). The results suggest that the proposed, 3D-bioprinted, subcutaneous construct can be a better alternative to portal vein islet transplantation.
Open peer comments: Debate/Discuss/Question/Opinion
<1>